Targeted Approaches to T-Cell Lymphoma

被引:1
|
作者
Harrop, Sean [1 ]
Abeyakoon, Chathuri [2 ]
Van der Weyden, Carrie [1 ]
Prince, H. Miles [1 ,3 ,4 ]
机构
[1] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia
[2] Monash Hlth, Melbourne, Vic 3168, Australia
[3] Epworth Healthcare, Melbourne, Vic 3002, Australia
[4] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic 3000, Australia
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 06期
关键词
novel agents; monoclonal antibodies; immunotherapy; NON-HODGKIN-LYMPHOMA; BRENTUXIMAB VEDOTIN; PHASE-II; MYCOSIS-FUNGOIDES; OPEN-LABEL; CD30; EXPRESSION; SEZARY-SYNDROME; PI3K-DELTA; GAMMA INHIBITOR; MONOCLONAL-ANTIBODY; PHYSICIANS CHOICE;
D O I
10.3390/jpm11060481
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The T-cell lymphomas are a rare group of Non-Hodgkin's lymphomas derived from mature T-lymphocytes. They are divided broadly into the Peripheral T-cell lymphomas and the Cutaneous T-cell lymphomas. Clinical outcomes vary widely but are generally unsatisfactory with current treatments. The development of an understanding of the various critical pathways in T-cell lymphogenesis and subsequent identification of therapeutic targets has led to a rapid expansion of the previously underwhelming T-cell lymphoma armament. This review aims to provide an up-to-date overview of the current state of targeted therapies in the T-cell lymphomas, including novel antibody-based treatments, small molecule inhibitors and immune-based therapies.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Targeted therapies for cutaneous T-cell lymphomas
    Kaplan, Jason B.
    Guitart, Joan
    Giles, Francis J.
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (04) : 481 - 493
  • [22] Angiogenesis in cutaneous T-cell lymphoma - proteomic approaches
    Tanase, Cristiana
    Popescu, Ionela Daniela
    Enciu, Ana-Maria
    Gheorghisan-Galateanu, Ancuta Augustina
    Codrici, Elena
    Mihai, Simona
    Albulescu, Lucian
    Necula, Laura
    Albulescu, Radu
    ONCOLOGY LETTERS, 2019, 17 (05) : 4060 - 4067
  • [23] Peripheral T-Cell Lymphoma, Not Otherwise Specified A Review of Current Disease Understanding and Therapeutic Approaches
    AI-Zahrani, Musa
    Savage, Kerry J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (02) : 189 - +
  • [24] Immunobiology and treatment of cutaneous T-cell lymphoma
    Goel, Rishi R.
    Rook, Alain H.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (08) : 985 - 996
  • [25] Update on Biology of Cutaneous T-Cell Lymphoma
    Phyo, Zaw H.
    Shanbhag, Satish
    Rozati, Sima
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [26] Brentuximab vedotin in systemic T-cell lymphoma
    Oki, Yasuhiro
    Younes, Anas
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 623 - 632
  • [27] Cutaneous T-cell Lymphoma
    Pulitzer, Melissa
    CLINICS IN LABORATORY MEDICINE, 2017, 37 (03) : 527 - +
  • [28] Recent progress in the pathophysiology and the treatment of epidermotropic cutaneous T-cell lymphoma
    Bagot, M.
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2019, 203 (8-9): : 701 - 705
  • [29] Novel target and treatment agents for natural killer/T-cell lymphoma
    Tian, Xiao-Peng
    Cao, Yi
    Cai, Jun
    Zhang, Yu-Chen
    Zou, Qi-Hua
    Wang, Jin-Ni
    Fang, Yu
    Wang, Jia-Hui
    Guo, Song-Bin
    Cai, Qing-Qing
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [30] Targeted treatment and new agents in peripheral T-cell lymphoma
    Zain, Jasmine M.
    O'Connor, Owen
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (01) : 33 - 44